Avalon Pharmaceuticals Identifies Small Molecule Inhibitors of the Aurora/Centrosome Cancer Pathway that Block PLK3 Protein Func
14 Abril 2008 - 12:00PM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today that
it has used AvalonRx�, its biomarker based drug discovery system,
to identify small molecule inhibitors of the Aurora/Centrosome
pathway, and to reveal the protein targeted by these compounds.
Their findings were announced today in a poster presentation
entitled �Identification of Small Molecule Inhibitors of the
Aurora/Centrosome Pathway,� at the American Association for Cancer
Research 2008 Annual Meeting, in San Diego, CA. These inhibitors
potently induce death in cancer cells and inhibit the Polo-Like
Kinase 3 (PLK3) protein, a key node in the centrosome pathway. The
Aurora/Centrosome pathway is critical for control of cellular
growth and chromosomal integrity in cancer cells, and is frequently
misregulated in cancer. �The Aurora/Centrosome pathway is important
in many cancers; therefore, we believe that the identification of
these allosteric inhibitors of the PLK3 protein is a significant
advancement in the development of potential therapeutics for
cancer,� said Dr. Stephen Horrigan, Avalon�s Vice President of
Research. Compounds in Avalon's lead small molecule series have
broad activity in cell lines from multiple cancers, while acting as
selective allosteric inhibitors of the PLK3 protein. PLK3 has been
recognized as a key regulator of cancer cell function whose
activation has been implicated in multiple cancer types, including
breast, lung and stomach. About Avalon Pharmaceuticals Avalon is a
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class cancer therapeutics. Avalon�s
lead product candidate, AVN944,�an IMPDH inhibitor, is in Phase II
clinical development. Avalon also has preclinical programs to
develop inhibitors of the Beta-catenin and Aurora/Centrosome
pathways,�discovery programs�for�inhibitors of�the Survivin�and
Myc�pathways and partnerships with Merck, AstraZeneca/MedImmune,
ChemDiv, Medarex, and Novartis. AvalonRx� is the Company�s
proprietary platform�which is based on�large-scale�biomarker
identification and monitoring, used to discover and develop
therapeutics for pathways that have historically been characterized
as "undruggable." Avalon is headquartered in Germantown, MD. Safe
Harbor Statement This announcement contains, in addition to
historical information, certain forward-looking statements that
involve risks and uncertainties. Such statements reflect the
current views of Avalon management and are based on certain
assumptions. Actual results could differ materially from those
currently anticipated as a result of a number of factors, risks and
uncertainties, including those specified under the �Risk Factors�
section of our 2007 Annual Report on Form 10-K and updates
contained in subsequent filings we make with the Securities and
Exchange Commission.
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Avalon Pharmaceuticals (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Avalon Pharmaceuticals, Inc.